. Author manuscript; available in PMC: 2009 Aug 1.

Published in final edited form as: J Hepatol. 2008 May 20;49(2):184–191. doi: 10.1016/j.jhep.2008.04.011

Table 1.

Characteristics of the 374 Virahep-C study participants who consented to participate in genetics studies.

	All (n=374)		AA (n=180)		CA (n=194)
	n	%SVR	n	%SVR	n	%SVR	p-value^††
Age (years) ^†
> 48	181	38.7%	93	24.7%	88	53.4%	0.586
≤ 48	193	43.0%	87	29.9%	106	53.8%
Gender (n, %)
Male	244	36.5%	118	23.7%	126	48.4%	0.015
Female	130	49.2%	62	33.9%	68	63.2%
Baseline viral level(per log10 IU/ml) ^†
≤ 6.5	192	45.8%	102	33.3%	90	60.0%	0.009
> 6.5	182	35.7%	78	19.2%	104	48.1%
Ishak fibrosis score
0	39	59.0%	18	50.0%	21	66.7%	0.012
1, 2	193	41.5%	97	25.8%	96	57.3%
3, 4	112	38.4%	54	24.1%	58	51.7%
5, 6	29	24.1%	10	20.0%	19	26.3%

Proportion maximum interferon dose taken for first 24 weeks ^†

≤ 0.96	185	29.7%	97	21.7%	88	38.6%	<0.0001
>0.96	182	53.3%	77	35.1%	105	66.7%
ALT(U/L) ^†
> 66	187	38.5%	76	21.1%	111	50.5%	0.071
≤ 66	187	43.3%	104	31.7%	83	57.8%

^†

cut-off values are medians.

^††

race-adjusted Mantel-Haenszel chi-square test